Janssen Research & Development: Daratumumab DARZALEXÂ Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration FDA for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma

RARITAN N.J. July 25 2016 PRNewswire &160;The U.S. Food and Drug Administration FDA has granted a Breakthrough Therapy Designation to the immunotherapy daratumumab DARZALEX&174; in combination with lenalidomide an immunomodulatory agent and dexamet...